Abbott Labs | StockChase
106
Abbott Labs (ABT-N)

Last Price Recorded: $55.5600 on 2017-11-17

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical

Abbott Labs


Signal Opinion Expert

2014-01-29

DON'T BUY
Abbott Labs (ABT-N)

Has really been falling. Results were a little mixed. Management was quite cautious and said the 2nd half was going to be a challenging time, partly because of difficult comparisons and partly because of the stronger US$. He just doesn’t see a catalyst and the price is a little too high for him.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $35.850
Owned: No

2014-01-02

BUY
Abbott Labs (ABT-N)

A good stable company. Sold his holdings when they spun off their pharmaceutical division. They are now left with medical devices, nutritional business and their diagnostic business. Have a wonderful record of growing dividends over the years. Very steady and he feels it is underappreciated.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $38.230
Owned: No

2013-12-23

COMMENT
Abbott Labs (ABT-N)

Sold his holdings a few months ago in order to look for other opportunities. Valuations are a little too excessive for him. He prefers to buy in the 12-13 times earnings range. Doesn’t see growth in this one.

biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Management

Price: $38.440
Owned: No

2013-12-09

TOP PICK
Abbott Labs (ABT-N)

Spun off drug side.  It is medical devices and has been one of the most consistent growers over the last decade.  Reasonably priced, 2.5% yield.

biotechnology/pharmaceutical
Gavin Graham

Trustee, Pointbreak ETFs

Price: $37.200
Owned: Yes

2013-11-29

PAST TOP PICK
Abbott Labs (ABT-N)

(A Top Pick Nov 26/12. Up 24.63%.) There was a spin out of Abbvie (ABBV-N) from this company

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $38.190
Owned: No

2013-11-01

TOP PICK
Abbott Labs (ABT-N)

Bought this because he was looking to increase his exposure to healthcare. Not that expensive. Nice diverse portfolio. Good exposure, both in North America and outside. Could be $42 over 12 months.

biotechnology/pharmaceutical
Stuart Hinshelwood

US Equities Specialist, BMO Nesbitt Burns

Price: $36.960
Owned: Yes

2013-10-30

PAST TOP PICK
Abbott Labs (ABT-N)

(A Top Pick Nov 19/12. Up 25.37%.) Spun off their branded pharmaceutical business last year and he offloaded the AbVie (ABBV-N) component and kept this part that was more focused on medical devices and nutritions. Still likes. Increased their dividend by 57%. Most recent quarter showed that they had made 2 acquisitions on the medical devices side in cataract surgery equipment. 3.2% dividend yield.

biotechnology/pharmaceutical
Mohsin Bashir

VP Investments, Stone Asset Management

Price: $36.940
Owned: Yes

2013-10-29

TOP PICK
Abbott Labs (ABT-N)

Adult and infant nutritionals.  Generics, very emerging market focused, diversified.  Good earnings growth going forward.  Very shareholder friendly.  Increasing dividend should attract more shareholders. 

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $37.280
Owned: Yes

2013-10-10

PAST TOP PICK
Abbott Labs (ABT-N)

(Top Pick Oct 11/12, Up 2.37%) Did well with Abvie as well.  He sold ABT.

biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Management

Price: $33.640
Owned: No

2013-10-04

HOLD
Abbott Labs (ABT-N)

Sold his holdings before the spinoff of their pharmaceutical side into AbbVie (ABBV-N). They are left with the nutritional, diagnostics and medical devices. Trading at about 14 or 15 times earnings. Growing at 11%-13% per year. Very, very stable company and a great core position in your portfolio.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $33.560
Owned: No

2013-09-19

TOP PICK
Abbott Labs (ABT-N)

Diversified healthcare company. Recently spun off their pharmaceutical business. Has some decent growth over the next couple of years. Thinks it can get to $42 over a 12-18 time period.

biotechnology/pharmaceutical
Stuart Hinshelwood

US Equities Specialist, BMO Nesbitt Burns

Price: $35.340
Owned: Yes

2013-09-18

PAST TOP PICK
Abbott Labs (ABT-N)

(A Top Pick Sept 4/12. Up 13.65%.) He would like to add to his holdings when he gets the opportunity.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc.

Price: $35.650
Owned: Yes

2013-07-29

TOP PICK
Abbott Labs (ABT-N)

Just moved up stop loss to $34.90 (200 day moving average).  They are in the right space.  Nutritional component looks to be just in the beginning of a long term uptrend.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc.

Price: $36.740
Owned: Yes

2013-07-09

TOP PICK
Abbott Labs (ABT-N)

Spun off their branded pharmaceutical business last year so now they have 40% in emerging markets and aiming to take closer to 50% over the next couple of years. Have some nutritional products along with their stents. Likes the product pipeline. Playing the increased demand for healthcare products in emerging markets through their branded generics. Continuing to see improved margins. Very attractive entry point. Yield of 1.6%.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $34.740
Owned: Yes

2013-05-31

BUY
Abbott Labs (ABT-N)

One of the better ways to play pharmaceuticals. Amongst the big Pharmas it is one of the few that actually held up through the big selloff of the patent expiries in the mid-2000. Has a yield of about 2%.

biotechnology/pharmaceutical
Gavin Graham

Trustee, Pointbreak ETFs

Price: $36.670
Owned: Yes

Showing 31 to 45 of 106 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.